Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
20.73
-0.86 (-3.98%)
At close: Feb 21, 2025, 4:00 PM
20.95
+0.22 (1.06%)
After-hours: Feb 21, 2025, 7:24 PM EST
Denali Therapeutics Employees
Denali Therapeutics had 445 employees as of December 31, 2023. The number of employees increased by 18 or 4.22% compared to the previous year.
Employees
445
Change (1Y)
18
Growth (1Y)
4.22%
Revenue / Employee
n/a
Profits / Employee
-$960,658
Market Cap
2.98B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
DNLI News
- 16 days ago - Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - GlobeNewsWire
- 5 weeks ago - Why Is Denali Therapeutics Stock Trading Higher On Wednesday? - Benzinga
- 6 weeks ago - Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains - Seeking Alpha
- 6 weeks ago - Denali Therapeutics ALS drug fails in mid-stage trial - Reuters
- 6 weeks ago - Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial - GlobeNewsWire
- 7 weeks ago - Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic - Benzinga
- 3 months ago - Denali Has A Neurodegenerative Edge Despite Market Skepticism - Seeking Alpha
- 3 months ago - Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire